[Hypergonadotropic amenorrhea (WHO III) as osteoporosis risk].
In 21 patients, suffering from amenorrhoeic hypergonadotropic ovarian insufficiency (age 27 +/- 3 years [FSH: 43 +/- 10, LH: 40 +/- 8]), the bone density was measured by single-photon densitometry (SPA), before starting a hormonal replacement therapy with oestrogen/progesterone. Every 5 months, the trend in bone density change was measured in all cases. The bone density before hormonal treatment was lower in the WHO III-group (1.36 +/- 0.21 g/cm; 1.09 +/- 0.26 g/cm2) than in the age-matched group (1.57 +/- 0.21 g/cm; 1.28 +/- 0.31 g/cm2). Bone density increased after hormonal therapy (p less than 0.05). These results point to the necessity of hormonal replacement therapy in cases of WHO III.
Metka
M
M
I. Univ.-Frauenklinik Wien.
Heytmanek
G
G
Enzelsberger
H
H
Huber
J
J
Kurz
C
C
Spona
J
J
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood*; D015519:Bone Density / Q000502:physiology; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008594:Menopause, Premature / Q000097:blood*; D010024:Osteoporosis / Q000097:blood*; D012307:Risk Factors
D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Die hypergonadotrope Amenorrhö (WHO III) als Osteoporoserisiko.